Tech Company Financing Transactions
Dispatch Bio Funding Round
Dispatch Bio secured a Series A funding round on 7/24/2025. Backers included Alexandria Venture Investments, Arch Venture Partners and Bristol Myers Squibb.
Transaction Overview
Company Name
Announced On
7/24/2025
Transaction Type
Venture Equity
Amount
Unknown
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to advance its therapeutic candidates into first-in-human clinical studies and beyond, with the first program expected to enter the clinic in 2026.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
953 Indiana St.
San Francisco, CA 94107
USA
San Francisco, CA 94107
USA
Phone
Undisclosed
Website
Email Address
Overview
Dispatch Bio was founded with a bold purpose: to help create a world where all cancer patients can be cured. To achieve this, we're engineering a universal treatment across solid tumors, leveraging our first-in-class Flare platform. Our novel approach combines the strengths of immunotherapy with a tumor-specific viral vector -- both engineered to clear tumor cells with precision and power -- to expand the curative potential of immunotherapies for cancer patients. Our vision is to empower people to continue forward with their lives -- cancer-free.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sabah Oney
Browse more venture capital transactions:
Prev: 7/24/2025: Rezolve AI venture capital transaction
Next: 7/24/2025: IdentifAI venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs